Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126011022 | 12601102 | 2 | F | 20140612 | 20160912 | 20160728 | 20160919 | EXP | FR-ABBVIE-16K-056-1683919-00 | ABBVIE | 26.00 | YR | M | Y | 95.00000 | KG | 20160919 | MD | COUNTRY NOT SPECIFIED | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126011022 | 12601102 | 1 | PS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | UNKNOWN | 125057 | 80 | MG | SOLUTION FOR INJECTION | ||||||
| 126011022 | 12601102 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QOW | |||||
| 126011022 | 12601102 | 3 | SS | INFLIXIMAB | INFLIXIMAB | 1 | Subcutaneous | U | UNKNOWN | 0 | 480 | MG | |||||||
| 126011022 | 12601102 | 4 | SS | INFLIXIMAB | INFLIXIMAB | 1 | Subcutaneous | U | UNKNOWN | 0 | 480 | MG | |||||||
| 126011022 | 12601102 | 5 | SS | USTEKINUMAB | USTEKINUMAB | 1 | Subcutaneous | D | UNKNOWN | 0 | 90 | MG | |||||||
| 126011022 | 12601102 | 6 | C | DAFALGAN | ACETAMINOPHEN | 1 | Oral | 0 | |||||||||||
| 126011022 | 12601102 | 7 | C | NUROFEN | IBUPROFEN | 1 | Oral | 0 | |||||||||||
| 126011022 | 12601102 | 8 | C | VENTOLINE | ALBUTEROL | 1 | 0 | ||||||||||||
| 126011022 | 12601102 | 9 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | 0 | 20 | MG | QD | |||||||||
| 126011022 | 12601102 | 10 | C | BETAMETASONE LFM | 2 | 0 | QD | ||||||||||||
| 126011022 | 12601102 | 11 | C | HYDROXYZINE | HYDROXYZINEHYDROXYZINE HYDROCHLORIDE | 1 | 1/DAY IF PRURITUS | 0 | 25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126011022 | 12601102 | 1 | Product used for unknown indication |
| 126011022 | 12601102 | 3 | Psoriasis |
| 126011022 | 12601102 | 5 | Product used for unknown indication |
| 126011022 | 12601102 | 6 | Product used for unknown indication |
| 126011022 | 12601102 | 7 | Product used for unknown indication |
| 126011022 | 12601102 | 8 | Product used for unknown indication |
| 126011022 | 12601102 | 9 | Product used for unknown indication |
| 126011022 | 12601102 | 10 | Product used for unknown indication |
| 126011022 | 12601102 | 11 | Pruritus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126011022 | 12601102 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126011022 | 12601102 | Pneumonia | |
| 126011022 | 12601102 | Pneumonia legionella | |
| 126011022 | 12601102 | Psoriasis | |
| 126011022 | 12601102 | Psoriatic arthropathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126011022 | 12601102 | 1 | 20140204 | 20140204 | 0 | |
| 126011022 | 12601102 | 2 | 20140211 | 20140617 | 0 | |
| 126011022 | 12601102 | 3 | 20140617 | 20140617 | 0 | |
| 126011022 | 12601102 | 4 | 20140703 | 0 | ||
| 126011022 | 12601102 | 5 | 201307 | 201311 | 0 |